MicroRNA-31 Functions As a Tumor Suppressor by Regulating Cell Cycle and Epithelial-mesenchymal Transition Regulatory Proteins in Liver Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Mar 24

PMID 25797269

Citations 67

Authors

Hyung Seok Kim

Kyo Sun Lee

Hyun Jin Bae

Jung Woo Eun

Qingyu Shen

Se Jin Park

Woo Chan Shin

Hee Doo Yang

Mijung Park

Won Sang Park

Yong-Koo Kang

Suk Woo Nam

Affiliations

Soon will be listed here.

Abstract

MicroRNA-31 (miR-31) is among the most frequently altered microRNAs in human cancers and altered expression of miR-31 has been detected in a large variety of tumor types, but the functional role of miR-31 still hold both tumor suppressive and oncogenic roles in different tumor types. MiR-31 expression was down-regulated in a large cohort of hepatocellular carcinoma (HCC) patients, and low expression of miR-31 was significantly associated with poor prognosis of HCC patients. Ectopic expression of miR-31 mimics suppressed HCC cell growth by transcriptional deregulation of cell cycle proteins. Additional study evidenced miR-31 directly to suppress HDAC2 and CDK2 expression by inhibiting mRNA translation in HCC cells. We also found that ectopic expression of miR-31 mimics reduced metastatic potential of HCC cells by selectively regulating epithelial-mesenchymal transition (EMT) regulatory proteins such as N-cadherin, E-cadherin, vimentin and fibronectin. HCC tissues derived from chemical-induced rat liver cancer models validated that miR-31 expression is significantly down-regulated, and that those cell cycle- and EMT-regulatory proteins are deregulated in rat liver cancer. Overall, we suggest that miR-31 functions as a tumor suppressor by selectively regulating cell cycle and EMT regulatory proteins in human hepatocarcinogenesis providing a novel target for the molecular treatment of liver malignancies.

Citing Articles

GeneAI 3.0: powerful, novel, generalized hybrid and ensemble deep learning frameworks for miRNA species classification of stationary patterns from nucleotides.

Singh J, Khanna N, Rout R, Singh N, Laird J, Singh I Sci Rep. 2024; 14(1):7154.

PMID: 38531923 PMC: 11344070. DOI: 10.1038/s41598-024-56786-9.

The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens.

Tavakoli Pirzaman A, Ebrahimzadeh Pirshahid M, Babajani B, Rahmati A, Niknezhad S, Hosseinzadeh R Technol Cancer Res Treat. 2023; 22:15330338231206003.

PMID: 37849311 PMC: 10586010. DOI: 10.1177/15330338231206003.

Retraction: MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1.

Lin Y, Xu T, Zhou S, Cui M Oncotarget. 2023; 14:579.

PMID: 37306518 PMC: 10259256. DOI: 10.18632/oncotarget.28446.

miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy.

Dziadkowiak E, Baczynska D, Wieczorek M, Olbromski M, Moreira H, Mrozowska M Oxid Med Cell Longev. 2023; 2023:2305163.

PMID: 37077658 PMC: 10110370. DOI: 10.1155/2023/2305163.

HDAC2 as a target for developing anti-cancer drugs.

Jo H, Shim K, Kim H, Jung H, Jeoung D Comput Struct Biotechnol J. 2023; 21:2048-2057.

PMID: 36968022 PMC: 10030825. DOI: 10.1016/j.csbj.2023.03.016.

References

Wszolek M, Rieger-Christ K, Kenney P, Gould J, Silva Neto B, Lavoie A . A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol. 2009; 29(6):794-801.e1. DOI: 10.1016/j.urolonc.2009.08.024. View

Zhang Y, Li Y, Lin C, Ding J, Liao G, Tang B . Aberrant upregulation of 14-3-3σ and EZH2 expression serves as an inferior prognostic biomarker for hepatocellular carcinoma. PLoS One. 2014; 9(9):e107251. PMC: 4165773. DOI: 10.1371/journal.pone.0107251. View

Lujambio A, Lowe S . The microcosmos of cancer. Nature. 2012; 482(7385):347-55. PMC: 3509753. DOI: 10.1038/nature10888. View

Asangani I, Harms P, Dodson L, Pandhi M, Kunju L, Maher C . Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012; 3(9):1011-25. PMC: 3663613. DOI: 10.18632/oncotarget.622. View

Maluccio M, Covey A . Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012; 62(6):394-9. DOI: 10.3322/caac.21161. View

Lin P, Chiu Y, Banerjee S, Park K, Mosquera J, Giannopoulou E . Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res. 2012; 73(3):1232-44. PMC: 3563734. DOI: 10.1158/0008-5472.CAN-12-2968. View

Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D . Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2012; 52(4):297-303. DOI: 10.1002/mc.21864. View

Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J . MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem. 2013; 288(13):9508-18. PMC: 3611019. DOI: 10.1074/jbc.M112.367763. View

Noh J, Chang Y, Kim M, Jung K, Kim J, Bae H . MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 2013; 335(2):455-62. DOI: 10.1016/j.canlet.2013.03.003. View

10.

Laurila E, Kallioniemi A . The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosomes Cancer. 2013; 52(12):1103-13. DOI: 10.1002/gcc.22107. View

11.

Noh J, Bae H, Eun J, Shen Q, Park S, Kim H . HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Cancer Res. 2014; 74(6):1728-38. DOI: 10.1158/0008-5472.CAN-13-2109. View

12.

Siow M, Ng L, Vincent-Chong V, Jamaludin M, Abraham M, Abdul Rahman Z . Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis. 2013; 20(4):345-51. DOI: 10.1111/odi.12118. View

13.

Puisieux A, Brabletz T, Caramel J . Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014; 16(6):488-94. DOI: 10.1038/ncb2976. View

14.

Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C . Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005; 41(2):307-14. DOI: 10.1002/hep.20538. View

15.

Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob S, Patel T . MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133(2):647-58. PMC: 4285346. DOI: 10.1053/j.gastro.2007.05.022. View

16.

Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz A, Wang Z . A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009; 137(6):1032-46. PMC: 2766609. DOI: 10.1016/j.cell.2009.03.047. View

17.

Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B . miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2009; 107(1):264-9. PMC: 2806773. DOI: 10.1073/pnas.0907904107. View

18.

Liu C, Tsai M, Hung P, Kao S, Liu T, Wu K . miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010; 70(4):1635-44. DOI: 10.1158/0008-5472.CAN-09-2291. View

19.

Xiong Y, Fang J, Yun J, Yang J, Zhang Y, Jia W . Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2009; 51(3):836-45. DOI: 10.1002/hep.23380. View

20.

Liu X, Sempere L, Ouyang H, Memoli V, Andrew A, Luo Y . MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010; 120(4):1298-309. PMC: 2846041. DOI: 10.1172/JCI39566. View